Next Article in Journal
Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease
Previous Article in Journal
Experience Applying the Guidelines for Reporting Reliability and Agreement Studies (GRRAS) Indicated Five Questions Should Be Addressed in the Planning Phase from a Statistical Point of View
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(4), 70; https://doi.org/10.3390/diagnostics8040070

Selenium and Selenoproteins in Immune Mediated Thyroid Disorders

1,2,3
,
4,5
,
1,5,6,7
and
1,3,5,*
1
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal
2
Serviço de Medicina 2B—Hospital de Santa Maria/Centro Hospitalar Lisboa Norte, 1649-035 Lisboa, Portugal
3
Department of Pathology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
4
Endocrinology Service, Hospital Center São João, 4200-319 Porto, Portugal
5
Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, 4200-135 Porto, Portugal
6
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, Portugal
7
Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
*
Author to whom correspondence should be addressed.
Received: 30 April 2018 / Revised: 21 September 2018 / Accepted: 29 September 2018 / Published: 4 October 2018
Full-Text   |   PDF [1088 KB, uploaded 4 October 2018]   |  

Abstract

Selenium is an essential micronutrient that is required for the synthesis of selenocysteine-containing selenoproteins, processing a wide range of health effects. It is known that the thyroid is one of the tissues that contain more selenium. The “selenostasis” maintenance seems to contribute to the prevention of immune mediated thyroid disorders. Prospective, observational studies, randomized, controlled studies evaluating selenium supplementation, and review articles that are available in Medline and PubMed have undergone scrutiny. The differences concerning methodology and results variability have been analyzed. Several authors support the idea of a potential efficacy of selenium (mainly selenomethionine) supplementation in reducing antithyroperoxidase antibody levels and improve thyroid ultrasound features. In mild Graves’ orbitopathy, selenium supplementation has been associated with a decrease of the activity, as well as with quality of life improvement. Future research is necessary to clearly understand the selenium supplementation biologic effects while considering the basal selenium levels/biomarkers, selenoprotein gene polymorphisms that may be involved, underlying comorbidities and the major clinical outcomes. View Full-Text
Keywords: selenium; selenoproteins; essential trace element; supplements; autoimmune thyroid diseases; Hashimoto’s thyroiditis; Graves’ disease selenium; selenoproteins; essential trace element; supplements; autoimmune thyroid diseases; Hashimoto’s thyroiditis; Graves’ disease
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Santos, L.R.; Neves, C.; Melo, M.; Soares, P. Selenium and Selenoproteins in Immune Mediated Thyroid Disorders. Diagnostics 2018, 8, 70.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top